EA
MRNA icon

Emerald Advisers’s Moderna MRNA Stock Holding History

Emerald Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,736
Closed -$206K – 261
2024
Q2 		$206K Sell
1,736
-1,464
-46% -$185K 0.01% 210
2024
Q1 		$341K Sell
3,200
-1,936
-38% -$195K 0.01% 197
2023
Q4 		$511K Buy
5,136
+2,615
+104% +$220K 0.02% 174
2023
Q3 		$260K Buy
+2,521
New +$281K 0.01% 200
2021
Q2 		– Sell
-6,046
Closed -$792K – 298
2021
Q1 		$792K Buy
6,046
+690
+13% +$100K 0.03% 166
2020
Q4 		$560K Sell
5,356
-1,846
-26% -$187K 0.02% 189
2020
Q3 		$510K Buy
7,202
+2,072
+40% +$144K 0.02% 183
2020
Q2 		$329K Buy
+5,130
New +$281K 0.01% 200

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Emerald Advisers's MRNA Position: Q3 2024 in Review

Emerald Advisers sold out of Moderna (MRNA) in Q3 2024, closing a stake of 1,736 shares — an estimated $206K sold.

Emerald Advisers first reported a position in MRNA in Q2 2020 and held it in 8 quarters. The position peaked at $792K in Q1 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Emerald Advisers reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Emerald Advisers sold 1,736 Moderna shares in Q3 2024, an estimated $206K.
  • Emerald Advisers first reported a position in Moderna in Q2 2020 and held it in 8 quarters.
  • Emerald Advisers's Moderna position peaked at $792K in Q1 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Emerald Advisers's 13F filing for Q3 2024, filed 29 Oct 2024.